USE OF THE MEDICATION FINERENONE FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES MELLITUS: LITERATURE REVIEW

Abstract

Finerenone is a medication indicated for the treatment of people with chronic kidney disease associated with type 2 diabetes mellitus. It is a selective non-steroidal antagonist of the mineralocorticoid receptor. Thus, the medication acts selectively on both rinses and the heart. Objective: To carry out a literature review on the use of finerenone in patients with chronic kidney disease and type 2 diabetes and its cardiorenal benefits. Methodology: Using the search engines LILACS, Google Scholar and PubMed, applying keywords: “finerenone”, “treatment of chronic kidney disease”, “diabetes”, “inflammation” and “fibrosis”. Articles were included between the years 2020 and 2023. From this, 7 articles were selected. Results: Chronic kidney disease and type 2 diabetes are chronic diseases that lead to increased mortality rates, considering that both are detrimental to the reduction of the glomerular filtration rate, which has an impact on cardiovascular health. In this context, overactivation of the mineralocorticoid receptor results in fibrosis and inflammation at cardiac, renal and vascular levels. Based on the studies found, Finerenone inhibits the effects of overactivation of the mineralocorticoid receptor, reducing the progression of chronic kidney disease and cardiovascular mortality. Conclusion: The studies analyzed point to the cardiorenal benefits of early use.